Saturday, August 18, 2018
 
 
Company News: Page (1) of 1 - 08/10/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
The Guthy-Jackson Charitable Foundation Welcomes Christopher Clinton Conway as Executive Director
 
(August 10, 2018)

BEVERLY HILLS, Calif., Aug. 10, 2018 /PRNewswire/ -- The Guthy-Jackson Charitable Foundation is pleased to welcome Christopher Clinton Conway in the newly-created position of Executive Director.  Mr. Conway will serve as a highly-visible representative of the foundation and is responsible for planning, implementing and assessing the foundation's future direction.  Mr. Conway is an accomplished and globally engaged nonprofit leader serving high-net-worth individuals in pursuit of meaningful impact.

Christopher Clinton Conway

"We are proud to have Christopher on our team," said Co-Founder Victoria Jackson. "His experience and ability will not only help us, but the entire Neuromyelitis Optica (NMO) patient community, as we continue to spearhead advances in clinical research toward a cure. We are ready to show the world how the power of rare is reshaping the future of medicine."



"Bringing Christopher on board represents an exciting new era for our foundation," said Co-Founder Bill Guthy. "He will play a critical role leveraging resources and building strategic partnerships, which will place NMO in the spotlight like never before."

Mr. Conway launched his career assisting Former U.S. President Jimmy Carter and First Lady Rosalynn Carter pursue an innovative global health agenda at The Carter Center of Emory University.  Immediate past President & Executive Director of The Joffrey Ballet, Mr. Conway also held key development positions at the Los Angeles County Museum of Art (LACMA), and forged an historic partnership between the Doheny Eye Institute and UCLA Stein Eye Institute.

"Victoria's and Bill's entrepreneurial spirit and incisive business acumen directs transformative change in pursuit of a cure for NMO," said Mr. Conway.

A sought after speaker and consultant, Mr. Conway is well known for equal emphasis on outcomes, efficiency and style. Mr. Conway has a B.A. from the University of Illinois at Urbana-Champaign, College of Liberal Arts & Sciences.  Mr. Conway was a Visiting Scholar in Gift & Estate Tax, Northwestern University. Mr. Conway obtained his J.D. from Washington University in St. Louis.

About The Guthy-Jackson Charitable Foundation

Bill Guthy and Victoria Jackson have each achieved extraordinary success as self-made entrepreneurs. Bill may be best known as a founding principal partner of direct marketing giant Guthy-Renker—the infomercial/media pioneer—while Victoria, a Hollywood makeup artist turned businesswoman, revolutionized the beauty world as the founding CEO of the iconic brand, Victoria Jackson Cosmetics. Longtime philanthropists on behalf of many worthy causes, the couple shifted their focus closer to home in 2008, when their beautiful teenage daughter Ali was diagnosed with neuromyelitis optica (NMO)—a life-threatening autoimmune disease. Upon learning that even the top medical authorities knew little about NMO, Bill and Victoria moved at record speed to establish The Guthy-Jackson Charitable Foundation.

Over the past 10 years, The Guthy-Jackson Charitable Foundation has dedicated more than $55 million, funding 76 research projects in the quest to understand the pathophysiology and biochemistry of the rare autoimmune disease Neuromyelitis Optica (NMO) and its Spectrum Disorder (NMOSD). Supporting research that rewrote the book on how to diagnose NMO, the foundation passionately supports programs and awareness that elevate the clinical paradigm for NMO patients and improve options for treatment, prevention and a cure for this disease. To date, the foundation's milestones include:

  • Catalyzing innovative science finding new therapeutic targets and biomarkers in NMO/SD.
  • Launching of three Phase III clinical trials to test new NMO/SD therapies; others emerging.
  • Forming International Clinical Consortium for NMO/SD; 96 members from 30 countries.
  • Supporting the first-ever tolerization trial in NMO patients, representing a breakthrough cure in disease.

CONTACT INFORMATION

Contact Information:
Christopher Clinton Conway
Direct: (310) 562-7912
Email: [email protected]

Download the full press release online.
Individual hi-res files available upon request.

 

The Guthy-Jackson Charitable Foundation

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/the-guthy-jackson-charitable-foundation-welcomes-christopher-clinton-conway-as-executive-director-300695258.html

SOURCE The Guthy-Jackson Charitable Foundation

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA,Medicine,Disease,Surgery,Medication,Science,Chemistry,Business,Science,Presidential,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
  • Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

    Cancer
  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck
  • Colorado Pain Care Broadens Practice to Include Cancer Patient Treatment in Denver, CO and Surrounding Area
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines